Good morning :)
$
₹
Zymeworks Inc. Common Stock

Zymeworks Inc. Common Stock

ZYME

NASDAQ
Asset Logo

Zymeworks Inc. Common Stock

ZYME

NASDAQ
$29.643.15% (+0.90)
$
₹
$29.643.15% (+0.90)
High
—
—
Low
—
—
Returns
—
—
Loading...
1D
1W
1M
3M
6M
1Y
3Y
5Y
Max

Healthcare

Biotechnology

Mid Cap

With a market cap of $2.2B the stock is ranked 2093

Key Metrics

Key Metrics

PE TTM
PE TTM

Close price divided by the earnings per share for the trailing twelve months

—
PB
PB

Close price divided by the book value per share at the end of the most recent quarter

26.95
EPS TTM
EPS TTM

Net profit earned per share over the trailing twelve months (sum of the last 4 quarters)

$-2.02
PEG Ratio
PEG Ratio

Price-to-Earnings (P/E) ratio divided by the forecasted annual earnings per share (EPS) growth rate over the next five years

0
Profit Margin
Profit Margin

Net profit divided by the total revenue for the most recent financial year

0%
Dividend Yield
Dividend Yield

Annual dividend per share for the trailing twelve months divided by the close price

—

Analyst Ratings & Forecast

Analyst Ratings & Forecast

Detailed Forecast Detailed Forecast 

Based on 14 analysts reports

Buy
14 analysts
Hold
0 analyst
Sell
0 analyst

Price Upside

+40.06%

Earnings Growth

+207.74%

Rev. Growth

+179.74%

See Detailed Forecast

Company Profile

Company Profile

Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.
Zymeworks Inc., a biotechnology company, develops biotherapeutics for the treatment of cancer, inflammation, and autoimmune diseases. The company's platforms include Azymetric multispecific antibody platform; Drug Conjugate platform that includes a suite of proprietary cytotoxins comprising topoisomerase and microtubulin inhibiting toxins, stable linkers, and conjugation technologies; EFECT platform, which consists of a set of modifications to the Fc region of antibodies; and ProTECT, a tumor-specific immune co-stimulation platform. Its lead product candidates include Ziihera (zanidatamab-hrii), a bispecific antibody targeting HER2-expressing tumors; zanidatamab for the treatment of neoadjuvant populations, breast cancer, and other HER2-expressing cancers; Pasritamig, a bispecific T cell engager targeting human kallikrein 2 for the treatment monotherapy and castration resistant prostate cancer; ZW191, a clinical- antibody-drug conjugates (ADC) that targets folate receptor alpha expressing tumors, including ovarian, endometrial, and non-small cell lung cancers; ZW251, a clinical-stage ADC molecule for the treatment of glypican 3 expressing hepatocellular carcinoma; ZW220, an ADC that targets NaPi2b-expressing NSCLC and ovarian cancer; ZW209, a novel TriTCE targeting Delta-like ligand 3 -expressing tumor cells for the treatment of solid tumors; and ZW1528, a bispecific molecule to treat chronic obstructive pulmonary disease. It has strategic partnerships and collaborations with Jazz Pharmaceuticals plc; Bristol- Myers Squibb company; Celgene Alpine Investment Co. LLC; GlaxoSmithKline Intellectual Property Development Limited; Daiichi Sankyo Co., Ltd.; Merck Sharp & Dohme Research GmbH; and Janssen Biotech, Inc. Zymeworks Inc. was incorporated in 2003 and is based in Middletown, Delaware.

Peers

Compare with peers Compare with peers 

Peers

Compare with peers Compare with peers 
AbbVie Inc
ABBV
AbbVie Inc
P/E Ratio
50.65
50.65
1Y Return
31.59%
31.59%
Buy Reco %
79.31
79.31
Amgen Inc
AMGN
Amgen Inc
P/E Ratio
27.73
27.73
1Y Return
46.88%
46.88%
Buy Reco %
35.29
35.29
Gilead Sciences Inc
GILD
Gilead Sciences Inc
P/E Ratio
—
—
1Y Return
35.24%
35.24%
Buy Reco %
78.57
78.57
Vertex Pharmaceuticals Inc
VRTX
Vertex Pharmaceuticals Inc
P/E Ratio
35.33
35.33
1Y Return
31.43%
31.43%
Buy Reco %
81.25
81.25
Moderna Inc
MRNA
Moderna Inc
P/E Ratio
—
—
1Y Return
944.75%
944.75%
Buy Reco %
17.39
17.39
Compare with Peers

Forecast

Forecast

Price

Revenue

Earnings

Price Forecast

Price Forecast

Lower price growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The 12-month consensus target implies 40.06% growth, versus a trailing 3-year CAGR of 59.66%.

2026
Current$29.63Baseline
Analyst Target - 1 year
Target$41.5+40.06%

All values in $

202220232024202520262027$16.72$26.36$36.01Target+40.06%
2026
Current$29.63Baseline
Analyst Target - 1 year
Target$41.5+40.06%

All values in $

Revenue Forecast

Revenue Forecast

Higher revenue growth forecast versus trailing 3-year CAGR
Compares analyst forecast growth with historical annualized growth.

The next fiscal year's mean estimate implies 179.74% growth, versus a trailing 3-year CAGR of -36.43%.

2025
Current$105.96Baseline
Forecast for Dec 2026
High$323.2+205.01%
Average$296.42+179.74%
Low$284.91+168.87%

All values in $ Million

20212022202320242025202626.68412.4876.0176.30105.96Low+168.87%Average+179.74%High+205.01%
2025
Current$105.96Baseline
Forecast for Dec 2026
High$323.2+205.01%
Average$296.42+179.74%
Low$284.91+168.87%

All values in $ Million

Earnings Per Share Forecast

Earnings Per Share Forecast

2025
Current$-1.08Baseline
Forecast for Dec 2026
High$1.95+280.56%
Average$1.16+207.74%
Low$0.25+123.15%

All values in $

202120222023202420252026-4.111.77-1.73-1.61-1.08Low+123.15%Average+207.74%High+280.56%
2025
Current$-1.08Baseline
Forecast for Dec 2026
High$1.95+280.56%
Average$1.16+207.74%
Low$0.25+123.15%

All values in $

Financials

Financials

Income

Balance Sheet

Cash Flow

27.6
-19.6
2.5
-41.2
2.4
-44.1
4.5
-45
Q3 2025
Q4 2025
Q1 2026
Q2 2026
Revenue
Net Income
Financial YearQ1 2024Q2 2024Q3 2024Q4 2024Q1 2025Q2 2025Q3 2025Q4 2025Q1 2026Q2 2026
Total Revenue10.0319.241631.0327.1148.7227.612.512.404.59
Net Income-31.65-37.68-29.85-23.50-22.632.31-19.60-41.20-44.16-45.01
Net Profit Margin-315.58%-195.84%-186.56%-75.75%-83.49%4.75%-70.98%-1638.52%-1833.97%-980.80%
See CostsAll values in $ Million

Peers

Peers & Comparison

Peers & Comparison

Comparing 2 stocks from
HealthcareBiotechnology

Valuation

Returns

Forecast

ScreenerCompare valuation on Screener
StockPE TTMPE TTMPBPBPEG RatioPEG Ratio
Zymeworks Inc. Common Stock -26.950
AbbVie Inc50.6550.450.58
Amgen Inc27.7321.332.75
ScreenerCompare valuation on Screener

Price Comparison

Price Comparison

Compare ZYME with any stock or ETF
Compare ZYME with any stock or ETF
Comparing from
ZYME
ABBV
AMGN
Loading...

Frequently asked questions

  1. Zymeworks Inc. Common Stock (ZYME) share price today is $29.64 as of November 7, 2026 at 2:29 AM IST. The stock touched a day high of $29.90 and a day low of $28.60.

  2. Zymeworks Inc. Common Stock stock trades on NASDAQ under the ticker symbol ZYME.

  3. Zymeworks Inc. Common Stock's market capitalization is $2.22B as of November 7, 2026 at 2:29 AM IST.

  4. Zymeworks Inc. Common Stock's price-to-earnings (P/E) ratio is N/A as of November 7, 2026.

  5. Zymeworks Inc. Common Stock's price-to-book (P/B) ratio is 26.95 as of November 7, 2026.

  6. Yes, You can buy Zymeworks Inc. Common Stock shares from India through Tickertape, via our partnership with ViewTrade IFSC under the IFSCA Global Access framework, subject to RBI’s Liberalised Remittance Scheme (LRS) limits.

  7. Indian investors can buy Zymeworks Inc. Common Stock shares in three steps: 1. Search Zymeworks Inc. Common Stock on the Tickertape app and tap Invest. 2. Complete your one-time digital KYC. 3. Fund your account and buy from as low as $1 via fractional shares.

  8. Since Zymeworks Inc. Common Stock trades in USD, an Indian investor's INR returns depend on both the stock's price movement and the USD-INR exchange rate. If the rupee depreciates against the dollar, INR returns are boosted beyond the stock's USD return; if the rupee appreciates, INR returns are reduced.

  9. Indian investors can start investing in Zymeworks Inc. Common Stock (ZYME) shares from as little as $1 through fractional ownership on Tickertape - for example, $10 buys approximately 0.3373 shares at the current price of $29.64.

Loading...